Vandetanib and cabozantinib, with inhibitory activity against RET, VEGFR2 and other targets, have been approved for their ability to improve progression-free survival of MTC patients34,35 and tested in other RET-driven cancers36,37. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.